IN8bio, Inc. (INAB) compared with its closest peers (QNCX, JSPR, DYAI, CVM, INTS). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $33.82M | -2.0 |
| Jasper Therapeutics, Inc. (JSPR) | $26.29M | -0.5 |
| Dyadic International, Inc. (DYAI) | $25.49M | — |
| CEL-SCI Corporation (CVM) | $25.15M | -1.5 |
| Intensity Therapeutics, Inc. (INTS) | $15.88M | -0.0 |
| Passage Bio, Inc. (PASG) | $14.09M | -0.8 |
| Senti Biosciences, Inc. (SNTI) | $11.84M | -0.4 |
| Creative Medical Technology Holdings, Inc. (CELZ) | $8.64M | -0.8 |
| VivoSim Labs, Inc. (VIVS) | $4.25M | -0.3 |
| Calidi Biotherapeutics, Inc. (CLDI) | $3.41M | -0.2 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
INAB overview · INAB earnings · INAB financials · INAB KPIs · INAB investor relations · INAB ownership · INAB filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.